期刊文献+

常规分割立体定向适形放射治疗晚期胰腺癌28例临床观察 被引量:3

Conventional Fraction Stereotactic Conformal Radiotherapy for Advanced Pancreatic Carcinoma
下载PDF
导出
摘要 目的:探讨常规分割立体定向适形放射治疗晚期胰腺癌的临床效果。方法:对28例晚期胰腺癌患者进行了6MV-X线的常规分割立体定向适形放射治疗。利用体部立体定向框架及真空垫固定体位,CT扫描后输入到治疗计划系统中,根据肿瘤靶区、敏感器官和移动误差勾画GTV、CTV、和PTV,结合剂量-体积直方图选择最佳治疗方案,应用5~7个非共面野照射,80%~90%等剂量线包绕PTV,并以此为处方线,常规分割,每周5次,每次2Gy,总DT:60Gy~70Gy/42天~49天。结果:治疗后1~3个月,85.7%患者食欲改善,6例黄疸患者全部退黄,腹痛缓解者占60.7%,腹痛消失者占28.6%,肿瘤全消者占35.7%,肿瘤部分消失者占64.3%。1年生存率为76.5%(13/17),4例死于恶病质。结论:常规分割立体定向适形放射治疗能使晚期胰腺癌患者症状减轻,提高生活质量和延长生存期,尤其对年老体弱患者更宜选择该法治疗。 Objective: To seek an effective treatment of conventional fraction stereotactic conformal radiotherapy (C F S C R) for advanced pancreatic carcinoma. Methods: patients were treated by CFSCR of 6MVX-ray. Patients were fixed with vac-lok cushion of the device of stereotactic localization. the CT Scanning results of 28 cases of advanced pancreatic carcinoma were put into the treatment planning system. According to the target area of tumor, sensitive organs and moving error drew GTV, CTV and PTV. The best plan was selected in considering the dose-volume histogram. Using 5 to 7 beams of non-coplanar radiation ray were choosed. PTV were surrounded by 80%-90% isodose surves. Conventional fraction, 5 fractions per week, 2 GY per fraction, All patients received a total dose of 60 GY- 70GY /42-49 days. Results: In a period of one month to three months, after CFSCR, appetite was improved in 24 of 28 patients (85.7%), jaundice disappeared in 6 of 6 patients(100%), Abdominal pain was relieved in 17 of 28 patients (60.7%) and 8 patients were relieved completely (28.6%). the complete remission of tumor was 35.7% (10/28) and partial remission of tumor was 64.3% (18/28). One-year rate was 76.5%(13/17). As a consequence of cachexia, 4 patients died within 1 year. Conclusion: CFSCR for advanced pancreatic carcinoma may relieve symptoms. It is an effective approach to improve life quality and prolong survival time for advanced pancreatic carcinoma, especially lod and weak patients more suit to select CFSCR.
出处 《中国肿瘤临床》 CAS CSCD 北大核心 2004年第13期747-748,754,共3页 Chinese Journal of Clinical Oncology
关键词 常规分割 立体定向适形放射治疗 晚期胰腺癌 Conventional fraction Stereotactic conformal radiotherapy Advanced pancreatic carcinoma
  • 相关文献

参考文献6

二级参考文献7

  • 1林言箴 陈双 等.胰腺癌.肿瘤学[M].天津科学技术出版社,1996.1506-1547.
  • 2吴肇汉 汤钊猷.胰腺与壶腹腔周围肿瘤.现代肿瘤学[M].上海医科大学出版社,1993.857-867.
  • 3余同行,肿瘤预后学,1995年,503页
  • 4胡逸民,肿瘤放射治疗学,1994年,214页
  • 5贾振庚,中华外科杂志,1993年,32卷,163页
  • 6林言箴,肿瘤学,1996年,1506页
  • 7吴肇汉,现代肿瘤学,1993年,857页

共引文献635

同被引文献16

  • 1王毅,王翀,沈文,张龙江,郝明利.多螺旋CT在胰头癌切除评估中的临床应用[J].中国肿瘤临床,2006,33(15):885-887. 被引量:1
  • 2张洪波,陈龙华,吴德华,曹小飞.局部晚期胰腺癌的三维适形放疗结合动脉灌注化疗疗效及预后多因素分析[J].广东医学,2007,28(3):412-414. 被引量:3
  • 3Burris HA,Moore MJ,Anderson J,et al.Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer-a randomized trial[J].J Clin Oncol,1997,15:2403-2413.
  • 4Takahashi Y, Kitadai Y, Bucana CD, et al. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis,and proliferation of human colon cancer[J]. Cancer Res, 1995, 55(18): 3964-3968.
  • 5Weidner N, Intratumor microvessel density as a prognostic factor in cancer[J]. Am J Pathol, 1995, 147(1): 9-19.
  • 6Kong D, Ma D, Bai H, et al. Expression and characterization of the first kunitz domain of human tissue factor pathway inhibitor- 2[J], Biochem Biophys Res Commun, 2004, 324(4): 1179 - 1185.
  • 7Hube F, Reverdiau P, Iochmann S, et al. Computer model of the interaction of human TFPI-2 kunitz-type serine protease inhibitor with human plasmin[J]. Thromb Res, 2003, 111(3): 197- 198.
  • 8Du X, Chand HS, Kisiel W. Human tissue factor .pathway inhibitor-2 does not bind or inhibit activated matrix metaUoproteinase-1 [J]. Biochirn Biophys Acta, 2003, 1621 (3): 242 - 245.
  • 9Yanamandra N, Kondraganti S, Gondi CS, et al. Recombinant adeno--associated virus (rAAV) expressing TFPI-2 inhibits invasion, angiogenesis and tumor growth in a human glioblastoma cell line[J]. IntJ Cancer, 2005, 115(6): 998-1005.
  • 10Chand HS, Du X, Ma D, et al. The effect of human tissue factor pathway inhibitor--2 on the growth and metastasis of fibrosarcoma tumors in athymlc mlce[J]. Blood, 2004, 103(3): 1069-1077.

引证文献3

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部